Naveen Yalamanchi
Partner at RTW Investments
Naveen Yalamanchi
Partner at RTW Investments
New York, New York
Overview
Work Experience
Partner
2015 - Current
Portfolio manager at RTW - $6.5b AUM healthcare investment firm. www.RTWfunds.com
Co-Founder and Director
2015
A clinical stage gene therapy company. Lead indications include: Danon Disease, Fanconi Anemia, Pyruvate Kinase Deficiency. (NASDAQ: RCKT) www.rocketpharma.com
Board Observer
2019
Board Observer
2018
Chief Financial Officer
2020 - 2023
Health Sciences Acquisitions Corporation 2 (NASDAQ: HSAQ) completed a business combination with Orchestra Biomed (NASDAQ:OBIO) in Jan 2023.
Chief Financial Officer
2019 - 2019
Health Sciences Acquisitions Corporation (NASDAQ: HSAC) merged with Immunovant Ltd on December 18, 2019. The combined entity is "Immunovant, Inc" (NASDAQ: IMVT).
Board Observer
2017 - 2019
Healthcare Portfolio Manager
2011 - 2014
Managed the healthcare strategy for three funds (long/short mutual fund, market-neutral product, hedge fund) on the Calamos Arista platform -- subsidiary of Calamos Investments, a multi-billion asset management firm. covered all healthcare sub-sectors.
Portfolio Manager
2010 - 2011
Healthcare investment firm (former Davidson Kempner team)
Healthcare Analyst
2009 - 2009
Analyst at Millennium Partners. Covering healthcare, with special focus on medical devices, tools, diagnostics, services.